- Home
- BEDU vs BTAI Comparison
BEDU vs BTAI Comparison
Compare BEDU & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEDU | BTAI |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 49.2M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BEDU | BTAI |
|---|---|---|
| Price | $2.25 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 6.9K | ★ 588.4K |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $224,321,752.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $1.17 |
| 52 Week High | $2.28 | $9.26 |
Technical Indicators
Market Signals| Indicator | BEDU | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 67.79 | 51.15 |
| Support Level | $2.18 | $1.82 |
| Resistance Level | $2.20 | $2.30 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 70.00 | 59.89 |
Price Performance
Historical ComparisonAbout BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.